Trial Profile

Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lorlatinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms ALKALINE
Sponsors Pfizer

Most Recent Events

15 Feb 2024 Planned End Date changed from 1 Jul 2024 to 1 Nov 2024.
15 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jul 2024.
02 Nov 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com